DUTASTERIDE

DUTASTERIDE

PRODUCT IDENTIFICATION

CAS NO.

164656-23-9

DUTASTERIDE

EINECS NO.

FORMULA C₂₇H₃₀F₆N₂O₂

MOL WT. 528.53

H.S. CODE

TOXICITY

SYNONYMS Avodart; Avolve; Duagen;

(5alpha,17beta)-N-(2,5-Bis(trifluoromethyl)phenyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide; alpha,alpha,alpha,alpha',alpha',alpha'-Hexafluoro-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxy- 2',5'-xylidide; (4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(2,5-bis(trifluoromethyl)phenyl)-2,4a,4b,5,6,6a,7,8,9,9a,9b, 10,11,11a-tetradecahydro-4a,6a-dimethyl-2-oxo-1H-indeno(5,4-f)quinoline-7-carboxamide;

DERIVATION

CLASSIFICATION

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE white to almost white crystalline powder

MELTING POINT

BOILING POINT

SPECIFIC GRAVITY

SOLUBILITY IN WATER

VAPOR DENSITY

REFRACTIVE INDEX

NFPA RATINGS

AUTOIGNITION

FLASH POINT

STABILITY Stable under normal conditions.

EXTERNAL LINKS & GENERAL DESCRIPTION

Dutasteride: A synthetic 4-azasteroid compound with antiandrogenic activity. Dutasteride competitively and specifically binds to isoenzymes 1 and 2 of 5-alpha-reductase, forming stable enzyme complexes and inhibiting the conversion of testosterone to 5α-dihydrotestosterone (DHT); the reduction in DHT activity may mitigate or prevent enlargement of the prostate gland. The type 2 5-alpha-reductase isoenzyme is primarily active in the reproductive tissues while the type 1 isoenzyme is also active in skin and the liver. (http://www.cancer.gov/)

Benign prostatic hyperplasia (BPH) is an androgen dependent process with a multifactoral etiology that includes hormones, ageing, growth factors, and stromal-epithelial interactions. DHT levels in the prostate remain at normal levels despite the decrease in testosterone that occurs with ageing. Conversion of testosterone to DHT in peripheral tissues may have implications in treating BPH. Finasteride inhibits 5-alpha-reductase type 2, with little affinity for type 1. It has been shown to be effective in lowering DHT levels by approximately 70% leading to a reduction in prostate volume and improved symptoms in men with BPH. Dutasteride inhibits both type 1 and type 2 5-alpha-reductase isoenzymes, theoretically providing a greater suppression of DHT than a selective inhibitor.(http://www.pbm.va.gov/)

Treatment of benign prostatic hyperplasia (type I and type II 5-alpha-reductase inhibitor)
Product	CAS RN.
Bexlosteride	148905-78-6
Dutasteride	164656-23-9
Elagolix	834153-87-6
Fiduxosin	208993-54-8
Izonsteride	176975-26-1
Tamsulosin	106133-20-4

SALES SPECIFICATION

APPEARANCE

white to almost white crystalline powder

ASSAY

99.0 - 1.1.0%

LOSS ON DRYING

0.5% max

RESIDUE ON IGNITION

0.3% max

HEAVY METALS

20ppm max

TRANSPORTATION

PACKING

HAZARD CLASS

UN NO.

OTHER INFORMATION

Hazard Symbols: , Risk Phrases:36/37/38, Safety Phrases: 26-36

PRICE INFORMATION